Our data suggest that PPI use is associated with a significantly increased risk of relapse, in unadjusted analyses, for both those who were treated with metronidazole and those who were treated with vancomycin. However, this analysis has several limitations. Our conclusions are based on unadjusted numbers, so unaccounted-for confounders may affect the results. Nevertheless, in our logistic regression model PPI use remained an independent predictor of relapse when adjusted for other factors, including age, metronidazole treatment, antibiotic exposure, and length of stay. In addition, the number of patients in our study who received vancomycin alone was small. In the subgroup of patients who received both metronidazole and vancomycin, there was an extremely high relapse rate in those who were given a PPI versus those who were not. It is possible that those patients had treatment failure with metronidazole; however, our data collection technique did not allow for that level of granularity.
In summary, our retrospective cohort study suggests that the use of a PPI is a predictor of readmission independent of choice of treatment. However, our study was not designed to address whether the concurrent use of PPI and metronidazole might lead to primary treatment failures. Dr Daniell presents an interesting insight that certainly deserves more study.
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Identification of Clostridium difficile Ribotype 027 for the First Time in Mainland China
To the Editor-Although several studies have shown that the incidence of infection with Clostridium difficile is increasing in Asia as a consequence of widespread use of broad-spectrum antibiotics, 1 very little is known about the epidemiology of C. dij^cife-associated diarrhea in developing countries. The hypertoxigenic epidemic strain of C. difficile, named ribotype 027, has also rarely been detected in Asia, especially in China. In a retrospective study, we performed epidemiologic screening of patients with C. difficile infection (CDI) and investigated the characteristics and epidemiology of C. difficile-associated diarrhea in a large teaching hospital in South China. Fresh stool samples were collected from patients with suspected CDI over a 2-year period (December 2009-May 2012). Of the 3,660 stool samples, 572 (15.6%) were positive for C. difficile toxin by direct polymerase chain reaction (PCR). 4, 5 Logistic regression analysis showed that previous antibiotic use (P = .04) and CDI experience (P< .01) were significant risk factors for toxin-positive diarrhea. C. difficile ribotype 027 was not found, although 7 cases of specimens detected binary toxin successfully.
We also studied the relationship between CDI and inflammatory bowel disease. Stool specimens from 406 patients with inflammatory bowel disease, including 241 patients with Crohn's disease and 165 with ulcerative colitis, were collected from January 2010 to April 2013 in Nanfang Hospital. Thirtyfour patients with Crohn's disease and 34 patients with ulcerative colitis were positive for C. difficile, with positive rates of 14.1% and 20.6%, respectively. Three stool samples were The total of 10 C. difficile strains that tested positive for the binary toxin genes were isolated and further analyzed if they were ribotype 027. Only 1 strain isolated from the patient with Crohn's disease was characterized as ribotype 027 by PCR ribotyping. 68 Sequence analysis of tcdC showed a single base pair (bp) deletion and a well-documented 18-bp deletion; the rest of the sequence was identical to the sequence results for the reference strain (API10463; Figure l) . 6 ' 910 The results were confirmed by Gene Xpert (Cepheid, GX-XVI), which detects the toxin B gene (tcdB), the binary toxin gene (cdt), and the tcdC gene deletion at nt 117.
Characteristics of the patient with C. difficile ribotype 027 were analyzed. On October 29, 2012, a 44-year-old female patient with chronic abdominal pain and recurrent diarrhea (6 or more bowel movements per day) lasting for 3 years was admitted to Nanfang Hospital. She and her family members had never been abroad before. Medical history included hospitalizations in a local hospital because of enterophthisis and antitubercular therapy (isoniazid, rifampin, streptomycin), but her condition did not improve. In 2011, she was admitted to Nanfang Hospital and received a diagnosis of Crohn's disease. The patient was treated with long-term mesalazine and dexamethasone and later 3 infusions of infleximab therapy. During her October 2012 admission, she developed a relapse of diarrhea and tested positive for C. difficile ribotype 027. She recovered after 2 weeks of oral vancomycin treatment. No relapse of CDI was reported over the next 5 months. During these months, she was readmitted 4 times for treatment of Crohn's disease and each time tested for CDI. However, C. difficile was isolated from her bowel movements again on July 8, 2013. Toxigenic culture and PCR ribotyping demonstrated that the bacterial pathogen causing the diarrhea was C. difficile ribotype 027. Genomics and restriction endonuclease analysis showed that both infections were caused by the same ribotype 027 strain.
C. difficile is the cause of many cases of antibiotic-or immunosuppressant-associated diarrhea worldwide. Given the epidemic potential and the severity of the disease, especially among the elderly population, surveillance of C. difficile must be introduced along with enhanced prevention and treatment strategies.
Antituberculosis agents are rarely associated with CDI. Among these agents, only rifampin is thought to be a cause of CDI, because of its antibiotic effect on a wide range of bacteria, whereas isoniazid and efhambutol have little or no activity against anaerobes. The patient underwent a period of rifampicin treatment, which supports the premise that antituberculosis treatment may be a risk factor for CDI. The patient was also treated with 3 infusions of infleximab, which demonstrates the importance of identifying risk factors-such as previous hospitalization, antibiotic therapy, and immunosuppression-in the development of C. dij^cife-associated diarrhea.
C. difficile may be an important emerging pathogen in Asia, because it has a strong impact on healthcare systems and costs. CDI can prolong hospital stay and strain hospital systems struggling with high occupancy rates. The aging demographic trend in China may worsen CDI rates, given the increased risk of this disease in elderly patients. The recent detection of C. difficile PCR ribotype 027 in multiple Asian countries calls for continued vigilance in clinical and laboratory surveillance, enhanced infection control, and active antimicrobial stewardship so as to address this emerging threat. CDI caused by the hypervirulent strain 027 had never been officially reported in Mainland China before this report. We strongly advise microbiological laboratories to cultivate toxin A-and toxin B-positive stool samples and to apply typing methods to the isolates to obtain more insight into the C. difficile types circulating throughout Asia. In summary, the epidemic C. difficile 027 strain is now present in China, and enhanced screening for this ribotype in other regions of the country is urgently needed.
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Potential conflicts of interest. All authors report no conflicts of interest relevant to this article. All authors submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest, and the conflicts that the editors consider relevant to this article are disclosed here. In a comparison of the A. baumannii MIC 50/90 during the pre-and postchlorhexidine advanced source control periods, the most common specimens were sputum (70/100; 70%) and blood cultures (11/100; 11%). Most clinical specimens were submitted from intensive care units (70/100; 70%) and medical units (15/100; 15%). There was an overall increase in chlorhexidine consumption and A. baumannii chlorhexidine MIC 50/90 among all hospital units and all infection sites after implementing advanced source control (Table 1) . Although there was a correlation between chlorhexidine consumption and A. baumannii chlorhexidine MIC (r = 0.69, P = .01), the incidence of XDR A. baumannii did not increase across hospital units or specimen sources (Tablel).
The mechanism of chlorhexidine resistance in A. baumannii is purportedly associated with bacterial efflux pumps. 10 In this study, although the magnitude of chlorhexidine exposure resulting in the increase in A. baumannii chlorhexidine MICs 50/90 during the 12-month advanced source control period, it did not achieve the threshold for the emergence of chlorhexidine-resistant XDR A. baumannii detection, yet our data suggest that ongoing active surveillance for chlorhexidineresistant A. baumannii as well as its MIC 50/90 is needed to evaluate the emergence of chlorhexidine-resistant A. baumannii.
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